Adeno-associated virus (AAV)-vectored delivery of HIV-1 broadly neutralizing antibodies (bNAbs) holds promise for achieving durable HIV-1 immunity in a practical and scalable way, yet AAV-encoded bNAbs often elicit antidrug antibody (ADA) responses that limit transgene expression. Engagement of T cell-expressed CD28 with its ligands CD80/CD86 on professional antigen-presenting cells is crucial for initiating adaptive immunity. Because the immunoglobulin-fusion protein CTLA4Ig can outcompete CD28 for binding to CD80/CD86, CTLA4Ig can inhibit T cell activation and prevent immune responses. Hence, we hypothesized that co-delivering CTLA4Ig during AAV/bNAb administration would prevent ADAs in primates. Six rhesus macaques (RMs) were treated intramuscularly with AAV-1 vectors encoding “rhesusized” (rh) versions of the bNAbs 3BNC117 (IgG1) and 10-1074 (IgG2). The experimental monkeys (n = 3) were dosed intravenously with 20 mg/kg of rh-CTLA4Ig on days 0, 2, 7, and 14, while the control animals (n = 3) did not receive any additional intervention. The experimental monkeys mounted ADAs that inhibited bNAb expression, albeit at different rates for rh-3BNC117-IgG1 (66%) and rh-10-1074-IgG2 (33%). In the control group, the incidence of ADAs leading to loss of bNAb expression was 100% for rh-3BNC117-IgG1 and 0% for rh-10-1074-IgG2. There was no significant difference between the groups in their cumulative levels of ADAs or bNAb expression measured over 20 weeks. Despite the development of ADAs against rh-3BNC117-IgG1 in five out of six animals, and in one out of six against rh-10-1074-IgG2, macaques in both groups exhibited minimal T cell responses to both bNAbs. AAV-1 capsid-specific CD4+ T cells trended higher in the control animals. In conclusion, a short course rh-CTLA4Ig did not significantly reduce the immunogenicity of AAV-encoded bNAbs in RMs. Although our study was not powered to detect marginal effects, robust improvements in AAV-driven expression of hypermutated HIV-1 bNAbs may require combination approaches, such as multiple co-stimulation blockers, pharmacological immunosuppression, and/or muscle-specific promoters.
BruelT, Guivel-BenhassineF, AmraouiS, et al.Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun, 2016; 7:10844; doi: 10.1038/ncomms10844
2.
CaskeyM, KleinF, LorenziJCC, et al.Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature, 2015; 522(7557):487–491; doi: 10.1038/nature14411
3.
LynchRM, BoritzE, CoatesEE, et al.; VRC 601 Study Team. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med, 2015; 7(319):319ra206; doi: 10.1126/scitranslmed.aad5752
4.
MendozaP, GruellH, NogueiraL, et al.Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature, 2018; 561(7724):479–484; doi: 10.1038/s41586-018-0531-2
5.
JulgB, StephensonKE, WaghK, et al.Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: A phase 1 clinical trial. Nat Med, 2022; 28(6):1288–1296; doi: 10.1038/s41591-022-01815-1
6.
GaeblerC, NogueiraL, StoffelE, et al.Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature, 2022; 606(7913):368–374; doi: 10.1038/s41586-022-04597-1
7.
SnellerMC, BlazkovaJ, JustementJS, et al.Combination anti-HIV antibodies provide sustained virological suppression. Nature, 2022; 606(7913):375–381; doi: 10.1038/s41586-022-04797-9
8.
BournazosS, KleinF, PietzschJ, et al.Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell, 2014; 158(6):1243–1253; doi: 10.1016/j.cell.2014.08.023
9.
WangD, TaiPWL, GaoG. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov, 2019; 18(5):358–378; doi: 10.1038/s41573-019-0012-9
10.
GardnerMR. Promise and progress of an HIV-1 cure by adeno-associated virus vector delivery of anti-HIV-1 biologics. Front Cell Infect Microbiol, 2020; 10:176; doi: 10.3389/fcimb.2020.00176
11.
FuchsSP, DesrosiersRC. Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol Ther Methods Clin Dev, 2016; 3:16068; doi: 10.1038/mtm.2016.68
12.
Martinez-NavioJM, FuchsSP, PantrySN, et al.Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression. Immunity, 2019; 50(3):567–575; doi: 10.1016/j.immuni.2019.02.005
13.
Martinez-NavioJM, FuchsSP, MendesDE, et al.Long-term delivery of an anti-SIV monoclonal antibody with AAV. Front Immunol, 2020; 11:449; doi: 10.3389/fimmu.2020.00449
14.
Martinez-NavioJM, FuchsSP, Pedreño-LópezS, et al.Host anti-antibody responses following adeno-associated virus-mediated delivery of antibodies against HIV and SIV in rhesus monkeys. Mol Ther, 2016; 24(1):76–86; doi: 10.1038/mt.2015.191
15.
PriddyFH, LewisDJM, GelderblomHC, et al.Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: A phase 1 randomised controlled trial. Lancet HIV, 2019; 6(4):e230–e239; doi: 10.1016/S2352-3018(19)30003-7
16.
CasazzaJP, CaleEM, NarpalaS, et al.; VRC 603 Study Team. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: A phase 1 dose-escalation trial. Nat Med, 2022; 28(5):1022–1030; doi: 10.1038/s41591-022-01762-x
17.
JenkinsMK, SchwartzRH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med, 1987; 165(2):302–319; doi: 10.1084/jem.165.2.302
18.
LarsenCP, ElwoodET, AlexanderDZ, et al.Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature, 1996; 381(6581):434–438; doi: 10.1038/381434a0
19.
LenschowDJ, ZengY, ThistlethwaiteJR, et al.Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science, 1992; 257(5071):789–792; doi: 10.1126/science.1323143
20.
LinH, BollingSF, LinsleyPS, et al.Long-term acceptance of major histo-compatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med, 1993; 178(5):1801–1806; doi: 10.1084/jem.178.5.1801
21.
SchroderPM, FitchZW, SchmitzR, et al.The past, present, and future of costimulation blockade in organ transplantation. Curr Opin Organ Transplant, 2019; 24(4):391–401; doi: 10.1097/MOT.0000000000000656
22.
KremerJM, WesthovensR, LeonM, et al.Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med, 2003; 349(20):1907–1915; doi: 10.1056/NEJMoa035075
23.
GenoveseMC, BeckerJ, SchiffM, et al.Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med, 2005; 353(11):1114–1123; doi: 10.1056/NEJMoa050524
24.
RupertoN, LovellDJ, QuartierP, et al.; Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled withdrawal trial. Lancet, 2008; 372(9636):383–391; doi: 10.1016/S0140-6736(08)60998-8
25.
RostaingL, VincentiF, GrinyóJ, et al.Long-term belatacept exposure maintains efficacy and safety at 5 years: Results from the long-term extension of the BENEFIT study. Am J Transplant, 2013; 13(11):2875–2883; doi: 10.1111/ajt.12460
26.
BernettMJ, ChuSY, LeungI, et al.Immune suppression in cynomolgus monkeys by XPro9523. MAbs, 2013; 5(3):384–396; doi: 10.4161/mabs.23976
27.
WilkinsonI, AndersonS, FryS, et al.Fc-engineered antibodies with immune effector functions completely abolished. PLoS One, 2021; 16(12):e0260954; doi: 10.1371/journal.pone.0260954
28.
KoSY, PeguA, RudicellRS, et al.Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature, 2014; 514(7524):642–645; doi: 10.1038/nature13612
29.
KimJH, LeeSR, LiLH, et al.High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One, 2011; 6(4):e18556; doi: 10.1371/journal.pone.0018556
30.
RyanMD, KingAM, ThomasGP. Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J Gen Virol, 1991; 72(11):2727–2732; doi: 10.1099/0022-1317-72-11-2727
31.
MuhuriM, ZhanW, MaedaY, et al.Novel combinatorial microRNA-binding sites in AAV vectors synergistically diminish antigen presentation and transgene immunity for efficient and stable transduction. Front Immunol, 2021; 12:674242; doi: 10.3389/fimmu.2021.674242
32.
FuchsSP, Martinez-NavioJM, Piatak JrM, et al.AAV-delivered antibody mediates significant protective effects against SIVmac239 challenge in the absence of neutralizing activity. PLoS Pathog, 2015; 11(8):e1005090; doi: 10.1371/journal.ppat.1005090
DouthwaiteJ, MoisanJ, PrivezentzevC, et al.A CD80-biased CTLA4-Ig fusion protein with superior in vivo efficacy by simultaneous engineering of affinity, selectivity, stability, and FcRn binding. J Immunol, 2017; 198(1):528–537; doi: 10.4049/jimmunol.1600682
35.
ReynoldsMR, WeilerAM, PiaskowskiSM, et al.A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine, 2012; 30(30):4465–4475; doi: 10.1016/j.vaccine.2012.04.082
36.
AdriouchS, FranckE, DrouotL, et al.Improved immunological tolerance following combination therapy with CTLA-4/Ig and AAV-mediated PD-L1/L2 muscle gene transfer. Front Microbiol, 2011; 2:199; doi: 10.3389/fmicb.2011.00199
37.
FrentschM, JappAS, DingeldeyM, et al.Blockade of the costimulatory CD28-B7 family signal axis enables repeated application of AAV8 gene vectors. J Thromb Haemost, 2020; 18(5):1075–1080; doi: 10.1111/jth.14757
38.
HerzogRW. Immune responses to AAV capsid: Are mice not humans after all? Mol Ther, 2007; 15(4):649–650; doi: 10.1038/sj.mt.6300123
39.
GernouxG, WilsonJM, MuellerC. Regulatory and exhausted T cell responses to AAV capsid. Hum Gene Ther, 2017; 28(4):338–349; doi: 10.1089/hum.2017.022
40.
LinYY, BelleI, BlasiM, et al.Skeletal muscle is an antigen reservoir in integrase-defective lentiviral vector-induced long-term immunity. Mol Ther Methods Clin Dev, 2020; 17:532–544; doi: 10.1016.j.omtm.2020.03.008
41.
BorowskiAB, BoesteanuAC, MuellerYM, et al.Memory CD8+ T cells require CD28 costimulation. J Immunol, 2007; 179(10):6494–6503; doi: 10.4049/jimmunol.179.10.6494
42.
MoretFM, BijlsmaJWJ, LafeberFPJG, et al.The efficacy of abatacept in reducing synovial T cell activation by CD1C myeloid dendritic cells is overruled by the stimulatory effects of T cell-activating cytokines. Arthritis Rheumatol, 2015; 67(3):637–644; doi: 10.1002/art.38982
43.
GrabsteinKH, EisenmanJ, ShanebeckK, et al.Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science, 1994; 264(5161):965–968; doi: 10.1126/science.8178155
44.
CuiG, HaraT, SimmonsS, et al.Characterization of the IL-15 niche in primary and secondary lymphoid organs in vivo. Proc Natl Acad Sci U S A, 2014; 111(5):1915–1920; doi: 10.1073/pnas.1318281111
45.
HutloffA, DittrichAM, BeierKC, et al.ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature, 1999; 397(6716):263–266; doi: 10.1038/16717
46.
KaminskiDA, LeeBO, EatonSM, et al.CD28 and inducible costimulator (ICOS) signalling can sustain CD154 expression on activated T cells. Immunology, 2009; 127(3):373–385; doi: 10.1111/j.1365-2567.2008.02991.x
47.
TakahashiN, KojimaT, KanekoA, et al.Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: Effect of concomitant methotrexate after 24 weeks. J Rheumatol, 2015; 42(5):786–793; doi: 10.3899/jrheum.141288
48.
CordobaF, WieczorekG, AudetM, et al.A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion. Am J Transplant, 2015; 15(11):2825–2836; doi: 10.1111/ajt.13377
49.
ElguetaR, BensonMJ, de VriesVC, et al.Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev, 2009; 229(1):152–172; doi: 10.1111/j.1600-065X.2009.00782.x
50.
TangQ, HenriksenKJ, BodenEK, et al.Cutting edge: CD28 controls peripheral homeostasis of CD4+ CD25+ regulatory T cells. J Immunol, 2003; 171(7):3348–3352; doi: 10.4049/jimmunol.171.7.3348
51.
Baecher-AllanC, BrownJA, FreemanGJ, et al.CD4+CD25high regulatory cells in human peripheral blood. J Immunol, 2001; 167(3):1245–1253; doi: 10.4049/jimmunol.167.3.1245
52.
WangCJ, PetersoneL, EdnerNM, et al.Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulation that inhibits autoimmunity. Nature Commun, 2022; 14(1):5724; doi: 10.1038/s41467-022-34477-1
53.
KarakusU, SahinD, MittlPRE, et al.Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species. Sci Transl Med, 2020; 12(574):eabb9283; doi: 10.1126/scitranslmed.abb9283
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
